Latest Breaking News On - Company tetanus - Page 1 : comparemela.com

Ultimovacs ASA: Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

No safety concerns found in first two dose level cohortsEnables progression to highest dosing level in assessment of Ultimovacs' second vaccine technology platform Oslo, 3 February 2022: Ultimovacs

Joachim midttunMary ann changCompany tetanusOslo university hospitalTetanus epitope targetingDrug safety monitoring boardChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities tradingFinance manager

Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Mary ann changCompany tetanusOslo university hospitalTetanus epitope targetingDrug safety monitoring boardChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities trading

Investegate |Ultimovacs ASA Announcements | Ultimovacs ASA: Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Investegate announcements from Ultimovacs ASA, Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Mary ann changHans vassgCompany tetanusOslo university hospitalUltimovacs begins dosingSecond cohortTetanus epitope targetingChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities tradingInvestegate announcementsInvestegate company announcementsUltimovacs asaLobenewswire and globenewswire

Ultimovacs ASA: Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

First patient in second cohort dosed with 400 µg of TET vaccineDSMB found no safety concerns for first cohort of three patients at 40 µg dose Oslo, 1 October 2021: Ultimovacs ASA ("Ultimovacs") (OSE

Mary ann changHans vassgCompany tetanusOslo university hospitalTetanus epitope targetingChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities trading

Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU

First patient in second cohort dosed with 400 μg of TET vaccineDSMB found no safety concerns for first cohort of three patients at 40 μg dose OSLO,.

Mary ann changHans vassgCompany tetanusOslo university hospitalTetanus epitope targetingChief medical officerUltimovac tetanus epitope targetingAnn changOslo stock exchange ultiUltimovacs asa